Two of the frontrunners in finding a viable medicine against COVID-19 are now able to resume their tests.
The week started with promising news from two of the companies that are working on a potential COVID-19 vaccine.
AstraZeneca and Johnson & Johnson announced that they are ready to resume the temporarily paused vaccine trials. The decision to halt the trails came after each of them reported that a volunteer got unexpectedly sick.
AstraZeneca was authorized by the US Food and Drug Administration to restart the trials after an inquiry showed that the global safety data showed that it's all safe. AstraZeneca's trial was held in September in the UK after a person developed a neurological condition.
Johnson & Johnson's trial was paused earlier this October after a participant reported an "unexpected illness." At the end of last week, JnJ stated that "no clear cause" led to the illness and that "preparations to resume the trial in the United States are now underway." No clear date was specified when the trial will resume, but according to people familiar with the matter, the event will probably occur next week.
According to government health officials and independent experts, these temporary pauses are setting an example of how safety processes work.
Read more about JnJ's situation here!
Sources: edition.cnn.com, finance.yahoo.com
Utilizatorii/cititorii nu ar trebui să se bazeze exclusiv pe informațiile prezentate aici și ar trebui să facă propriile lor cercetări/analize, prin citirea cercetărilor de bază. Conținutul acestui document este generic și nu ia în considerare circumstanțele personale ale fiecărui individ, experiența de investiții sau situația financiară actuală.
Prin urmare, Key Way Investments Ltd nu va accepta nicio responsabilitate pentru eventualele pierderi ale traderilor datorate utilizării conținutului sau a conținutului informațiilor prezentate în acest document. Performanțele trecute și previziunile nu sunt indicatori fiabili ai rezultatelor viitoare.